Koss-Olinger Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History

Koss-Olinger Consulting’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-370	Closed	-$235K	–	326
2025 Q1	$235K	Buy	+370	New	+$254K	0.02%	278
2024 Q4	–	Sell	-353	Closed	-$371K	–	267
2024 Q3	$371K	Buy	353 +24	+7%	+$26.7K	0.03%	198
2024 Q2	$346K	Buy	+329	New	+$319K	0.03%	193
2024 Q1	–	Sell	-320	Closed	-$281K	–	238
2023 Q4	$281K	Hold	320	–	–	0.03%	244
2023 Q3	$263K	Hold	320	–	–	0.04%	215
2023 Q2	$230K	Hold	320	–	–	0.03%	229
2023 Q1	$263K	Buy	320 +26	+9%	+$19.6K	0.03%	192
2022 Q4	$212K	Sell	294 -125	-30%	-$92.2K	0.03%	202
2022 Q3	$289K	Buy	419 +56	+15%	+$35.2K	0.05%	158
2022 Q2	$215K	Buy	363 +13	+4%	+$8.45K	0.04%	159
2022 Q1	$244K	Sell	350 -135	-28%	-$85.4K	0.04%	162
2021 Q4	$306K	Buy	485 +18	+4%	+$11.1K	0.05%	154
2021 Q3	$283K	Buy	+467	New	+$290K	0.05%	181

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Koss-Olinger Consulting's REGN Position: Q2 2025 in Review

Koss-Olinger Consulting sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 370 shares — an estimated $235K sold.

Koss-Olinger Consulting first reported a position in REGN in Q3 2021 and held it in 13 quarters. The position peaked at $371K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Koss-Olinger Consulting reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Koss-Olinger Consulting sold 370 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $235K.
Koss-Olinger Consulting first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 13 quarters.
Koss-Olinger Consulting's Regeneron Pharmaceuticals position peaked at $371K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Koss-Olinger Consulting's 13F filing for Q2 2025, filed 1 Aug 2025.